We are live on ! Find out more
CCM

Catalio Capital Management Portfolio holdings

AUM $479M
1-Year Est. Return 140.7%
This Fund
S&P 500
This Quarter Est. Return
+13.6%
1 Year Est. Return
+140.7%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$479M
AUM Growth
-$87.1M
Cap. Flow
-$83.1M
Cap. Flow %
-17.35%
Top 10 Hldgs %
54.46%
Holding
54
New
9
Increased
12
Reduced
13
Closed
13

Top Buys

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$31.3M
2
INCY icon
Incyte
INCY
+$18.2M
3
DFTX
Definium Therapeutics
DFTX
+$17.6M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$15.5M
5
CRVS icon
Corvus Pharmaceuticals
CRVS
+$14.2M

Top Sells

Rank Stock Value
1
BBOT
BridgeBio Oncology
BBOT
+$31.4M
2
LLY icon
Eli Lilly
LLY
+$27.9M
3
JNJ icon
Johnson & Johnson
JNJ
+$25M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$23M
5
GILD icon
Gilead Sciences
GILD
+$17.6M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBOT
51
BridgeBio Oncology
BBOT
$719M
– –
-410,700
Closed -$31.4M
GRAL
52
GRAIL Inc
GRAL
$3.1B
– –
-30,313
Closed -$2.59M
PVLA
53
Palvella Therapeutics
PVLA
$2.04B
– –
-10,452
Closed -$1.09M
BLLN
54
BillionToOne Inc
BLLN
$5.93B
– –
-25,505
Closed -$2.09M
1 2
3

Similar funds

FFG
Frisch Financial Group Melville, New York $478M AUM 16.28% 1-Year Est. Return
RFWA
RPg Family Wealth Advisory Burlington, Massachusetts $479M AUM 25.83% 1-Year Est. Return
SWM
Silverlake Wealth Management Williston, Vermont $479M AUM 17.75% 1-Year Est. Return
CMI
Clare Market Investments Dallas, Texas $478M AUM
TCM
Towneley Capital Management Laguna Hills, California $478M AUM 16.21% 1-Year Est. Return
LIM
Longfellow Investment Management Boston, Massachusetts $480M AUM 8% 1-Year Est. Return
MVP
Medina Value Partners Los Angeles, California $477M AUM 25.52% 1-Year Est. Return
YLHM
Yelin Lapidot Holdings Management Tel Aviv, Israel $480M AUM 42.17% 1-Year Est. Return

Catalio Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Catalio Capital Management held 54 positions worth $479M, down 15% from $566M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Catalio Capital Management withdrew a net $83.1M in Q1 2026, closing 13 positions and reducing 13 holdings. Its most notable exit was BridgeBio Oncology, an estimated $31.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Catalio Capital Management opened a new position in BridgeBio Pharma worth $32.1M.

  • Catalio Capital Management's largest Q1 2026 buy was BridgeBio Pharma: 432,014 shares worth $32.1M.
  • Catalio Capital Management added most to Ultragenyx Pharmaceutical in Q1 2026, an estimated $15.5M increase.
  • Catalio Capital Management's biggest Q1 2026 reduction was Gilead Sciences, cutting an estimated $17.6M.
  • Catalio Capital Management fully exited BridgeBio Oncology in Q1 2026, selling an estimated $31.4M.
  • Catalio Capital Management's ten largest holdings make up 54% of its $479M portfolio in Q1 2026.
  • Catalio Capital Management opened 9 new positions and closed 13 in Q1 2026.
  • Catalio Capital Management's portfolio value fell 15% quarter-over-quarter to $479M.

Based on Catalio Capital Management's 13F filing for Q1 2026, filed 15 May 2026.